Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Absci Q3 2026 Results: Net Loss of $33.3M, Loss Widens

Absci Corp reported a net loss for the third quarter of 2026 and continues to incur significant losses as it funds its Integrated Drug Creation platform and internal drug programs. As of October 30, 2026, the company had 172,745,810 shares of common stock outstanding and indicated a need for additional capital to fund future operations and clinical development.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.30.4
Profit before tax-33.3-28.6
Net income-33.3-28.7
EPS (diluted, $ a share)$-0.19$-0.20

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-19.6%
Source

10-Q filed with the SEC, NASDAQ: ABSI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Absci Corp: key numbers

Share price
$7.47Close, Nov 16
Market cap
$1.29B
Shares outstanding
172.75MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Absci Corp

All →
7:11 AM ET 8-K
Financial Results

Absci Financial Results

Absci Corp reported third quarter 2026 financial results and provided updates on its generative AI-designed therapeutic pipeline. The company is on track to release interim proof-of-concept data for its ABS-201 program in pattern hair loss in December 2026 and plans to initiate a Phase 2 trial for endometriosis in mid-2027.

“As we approach our first look at proof-of-concept data for ABS-201 next month, followed by full data early next year, we are excited for the opportunity to potentially demonstrate our program's ability to stimulate hair regrowth in a convenient and durable way.”

Sean McClain, Founder and CEO

“As ABS-201 progresses through the clinic, we have begun building our commercial infrastructure to support this and potential future programs. In line with that strategy, we are thrilled to be welcoming Gerry Muhle to Absci as our Chief Commercial Officer, whose experience we believe will position ABS-201 and our expanding program pipeline for success.”

Sean McClain, Founder and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.